Pixantrone联合利妥昔单抗对比吉西他滨联合利妥昔单抗治疗不适合移植的复发侵袭性B细胞非霍奇金淋巴瘤:III期随机多中心试验PIX306
PIX306是一项III期随机单盲多中心试验,纳入复发且不适合干细胞移植的DLBCL或FL 3级成人患者,随机接受Pixantrone+利妥昔单抗或吉西他滨+利妥昔单抗治疗。
要点
- Pixantrone联合利妥昔单抗未显著改善不适合移植的复发侵袭性B细胞淋巴瘤患者的PFS。
- 不良事件包括心脏事件的发生率两组无统计学显著差异。
核心结论
- Pixantrone联合利妥昔单抗对比吉西他滨联合利妥昔单抗未达到主要终点PFS。
主要发现
- 不良事件包括心脏事件的发生率两组无统计学显著差异。
关键数值与推荐
- Pixantrone 50 mg/m2或吉西他滨1000 mg/m2,第1、8、15天给药,28天为一周期,联合利妥昔单抗375 mg/m2第1天给药,最多6周期。
- 主要终点为PFS,次要终点包括OS、CR率、ORR和安全性。
临床怎么用
- 对于复发且不适合干细胞移植的侵袭性B细胞非霍奇金淋巴瘤患者,Pixantrone联合利妥昔单抗未显示优于吉西他滨联合利妥昔单抗的PFS获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PIX306 was a phase 3, randomised, single-blind, multicentre trial conducted in adult patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) grade 3 who relapsed after ≥1 rituximab-containing regimen and were not eligible for a stem cell transplant. Patients were randomised 1:1 to pixantrone 50 mg/m2 or gemcitabine 1000 mg/m2 on days 1, 8 and 15 of a 28-day cycle, combined with rituximab 375 mg/m2 on day 1, for up to six cycles. Patients were followed for up to 96 weeks. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), complete response (CR) rate, overall response rate (ORR) and safety. Overall, 312 patients were randomised (median age 73·0 years). The study did not meet its primary endpoint. Median PFS [95% confidence interval (CI)] was 7·3 months (5·2-8·4) with pixantrone + rituximab (PIX + R) and 6·3 months (4·4-8·1) with gemcitabine + rituximab [GEM + R; hazard ratio (HR): 0·85; 95% CI 0·64-1·14; P = 0·28]. Median OS was 13·3 (10·1-19·8) months with PIX + R and 19·6 (12·4-31·9) months with GEM + R (HR: 1·13; 95% CI 0·83-1·53). ORR was 61·9% and 43·9% respectively and CR rate 35·5% and 21·7%. The incidence of adverse events, including cardiac events, was not statistically significant different between PIX + R and GEM + R.
引用
- Pettengell R, Długosz-Danecka M, Andorsky D, et al. Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306). Br J Haematol. 2019. PMID: 31879945. doi:10.1111/bjh.16255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。